First scored analysis from the Warning Flags Head-to-Head NCE Edition, comparing Delix's zalsupindole and Gilgamesh's blixeprodil for MDD across seven risk categories.

We scored Transcend's TSND-201 methylone program through our risk estimator. Yellow flag. Here's what the model sees and what it means for investors.

The market priced in the policy tailwind. It priced in the voucher. Now it needs the next concrete event, and that event is Compass completing its NDA. Until then, the sector is in wait state.

On April 18, President Trump signed an executive order directing the FDA to fast-track psychedelic therapies. The market reacted broadly. The real question is which publicly traded companies can actually pull the trigger on expedited review, and when.

The FDA’s REMS framework is the biggest commercial bottleneck in psychedelic drug development, and companies are now engineering around it. Five concrete strategies already unfolding across the pipeline, from non-hallucinogenic neuroplastogens to digital safety layers.

We introduce five scientific pillars to systematically evaluate psychedelics and neuroplastogens, from receptor pharmacology to clinical outcomes. These pillars offer a framework to compare these modalities without bias, clarifying how each translates biological effects into therapeutic potential.

MM120, CYB-003, and GM2505 are redefining what psychedelic drug development looks like in practice. Three compounds, three approaches to tighter control over timing, dose, and clinical delivery.